We are live on ! Find out more
BVF Inc

BVF Inc Portfolio holdings

AUM $3.04B Turnover 10.42%
1-Year Est. Return 129.63%
This Fund
S&P 500
This Quarter Est. Return
+31.65%
1 Year Est. Return
+129.63%
3 Year Est. Return
+531.24%
5 Year Est. Return
+1,335.11%
10 Year Est. Return
+16,856.28%
AUM
$588M
AUM Growth
+$90.2M
Cap. Flow
-$14.6M
Cap. Flow %
-2.49%
Top 10 Hldgs %
70.6%
Holding
33
New
4
Increased
8
Reduced
8
Closed
3
Avg Time Held
1.5 years
Top 10 Avg Time Held
1.5 years
Top 20 Avg Time Held
1.5 years

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$40.5M
2
BLRX icon
BioLineRX
BLRX
+$18.8M
3
CTMX icon
CytomX Therapeutics
CTMX
+$16.4M
4
LOXO
Loxo Oncology
LOXO
+$13.2M
5
XOMA icon
Xoma
XOMA
+$6.17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.07%
2 Miscellaneous 0.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
BPMC icon
1
DELISTED
Blueprint Medicines
BPMC
$84.1M 14.3%
2,102,280
-1,153,000
-35% -$41.3M
2015 Q2
7 quarters
CCXI icon
2
DELISTED
ChemoCentryx
CCXI
$58.2M 9.89%
7,990,572
+192,000
+2% +$1.38M
2013 Q2
15 quarters
CYTK icon
3
Cytokinetics
CYTK
$7.19B
$54.8M 9.31%
4,260,836
-590,855
-12% -$6.91M
2013 Q2
15 quarters
ANAB icon
4
AnaptysBio
ANAB
$1.35B
$48.2M 8.21%
+1,738,600
New +$40.5M
2017 Q1
0 quarters
CNCE
5
DELISTED
Concert Pharmaceuticals
CNCE
$39.9M 6.78%
2,336,609
-279,640
-11% -$3.35M
2014 Q3
10 quarters
CTMX icon
6
CytomX Therapeutics
CTMX
$434M
$31.2M 5.3%
1,804,675
+1,249,869
+225% +$16.4M
2015 Q4
5 quarters
FWP
7
DELISTED
Forward Pharma
FWP
$29.9M 5.09%
198,265
– –
2014 Q4
9 quarters
INFI
8
DELISTED
Infinity Pharmaceuticals
INFI
$25.4M 4.32%
7,866,108
+5,300
+0.1% +$13K
2016 Q2
3 quarters
ARRY icon
9
DELISTED
Array Biopharma
ARRY
$24.7M 4.2%
2,763,086
-2,223,100
-45% -$23.7M
2013 Q2
15 quarters
CTIC
10
DELISTED
CTI BioPharma
CTIC
$18.8M 3.2%
4,479,691
-3
-0% -$14
2015 Q3
6 quarters
BLRX icon
11
BioLineRX
BLRX
$5.97M
$16.8M 2.86%
+29,167
New +$18.8M
2017 Q1
0 quarters
OMED
12
DELISTED
OncoMed Pharmaceuticals
OMED
$16.2M 2.76%
1,760,489
– –
2013 Q3
14 quarters
CBIO icon
13
Crescent Biopharma
CBIO
$556M
$15.3M 2.61%
28,263
– –
2016 Q2
3 quarters
ACHN
14
DELISTED
Achillion Pharmaceuticals
ACHN
$13.8M 2.35%
3,285,400
+862,100
+36% +$3.58M
2016 Q4
1 quarter
LOXO
15
DELISTED
Loxo Oncology
LOXO
$13.5M 2.29%
+320,000
New +$13.2M
2017 Q1
0 quarters
CASC
16
DELISTED
Cascadian Therapeutics
CASC
$13M 2.21%
3,133,224
– –
2013 Q2
15 quarters
XENE icon
17
Xenon Pharmaceuticals
XENE
$3.82B
$11.8M 2.01%
2,949,794
-94,011
-3% -$739K
2014 Q4
9 quarters
XOMA icon
18
DELISTED
Xoma
XOMA
$10.7M 1.82%
1,502,800
+1,200,000
+396% +$6.17M
2016 Q4
1 quarter
FATE icon
19
Fate Therapeutics
FATE
$127M
$8.85M 1.51%
1,945,245
-1,814,153
-48% -$6.64M
2016 Q4
1 quarter
IMDZ
20
DELISTED
Immune Design
IMDZ
$8.39M 1.43%
1,233,976
-86,188
-7% -$498K
2016 Q3
2 quarters
ARQL
21
DELISTED
Arqule
ARQL
$7.84M 1.33%
7,400,128
– –
2013 Q2
15 quarters
VIRX icon
22
DELISTED
Viracta Therapeutics
VIRX
$6.32M 1.07%
44,009
+4,217
+11% +$603K
2015 Q3
6 quarters
ALPN icon
23
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.44M 0.93%
466,119
– –
2015 Q4
5 quarters
ONCT icon
24
DELISTED
Oncternal Therapeutics
ONCT
$5.39M 0.92%
7,917
– –
2014 Q4
9 quarters
PVLA icon
25
Palvella Therapeutics
PVLA
$2.08B
$4.98M 0.85%
23,963
+778
+3% +$138K
2016 Q2
3 quarters

Similar funds

BVF Inc's Q1 2017 Portfolio in Review

As of Q1 2017, BVF Inc held 33 positions worth $588M, up 18% from $498M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

BVF Inc's Q1 2017 filing shows 4 new, 8 increased, 8 reduced and 3 closed positions. Its largest new stake was AnaptysBio: 1,738,600 shares worth $48.2M. The largest sale was Blueprint Medicines, an estimated $41.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

  • BVF Inc's largest Q1 2017 buy was AnaptysBio: 1,738,600 shares worth $48.2M.
  • BVF Inc added most to CytomX Therapeutics in Q1 2017, an estimated $16.4M increase.
  • BVF Inc's biggest Q1 2017 reduction was Blueprint Medicines, cutting an estimated $41.3M.
  • BVF Inc fully exited CoLucid Pharmaceuticals in Q1 2017, selling an estimated $17.6M.
  • BVF Inc's ten largest holdings make up 71% of its $588M portfolio in Q1 2017.
  • BVF Inc opened 4 new positions and closed 3 in Q1 2017.
  • BVF Inc's portfolio value rose 18% quarter-over-quarter to $588M.

Based on BVF Inc's 13F filing for Q1 2017, filed 15 May 2017.